iShares MSCI Intl Value Factor ETF
IVLU - ETF AI Analysis
Top Page
iShares MSCI Intl Value Factor ETF (IVLU)
IVLU, the iShares MSCI Intl Value Factor ETF, appears to be a solid, quality-focused fund, supported by strong holdings like Toyota, HSBC, Novartis, and Sanofi, which bring robust financial performance, reasonable valuations, and positive earnings outlooks. Some positions such as Shell, Roche, and Banco Santander introduce risks through revenue and cash flow challenges, valuation concerns, and regional or litigation issues. The main risk factor is the fund’s exposure to company-specific and regional issues across international value stocks, which can create periods of volatility even though the overall foundation is relatively strong.
IVLU vs. SPDR S&P 500 ETF (SPY)
- AUM
- 4.59B
- Region
- Developed Markets
- Expense Ratio
- 0.30%
- Beta
- 0.72
- Issuer
- iShares
- Inception Date
- Jun 16, 2015
- Dividend Yield
- 3.28%
- Asset Class
- Equity
- Index Tracked
- MSCI World ex USA Enhanced Value
IVLU Summary
IVLU is an ETF that follows the MSCI World ex USA Enhanced Value Index, focusing on stocks from developed countries outside the U.S. that look relatively cheap based on simple measures like price compared to earnings or assets. It holds many well-known international companies such as Toyota and Shell, and spreads your money across sectors like financials, industrials, and energy. Someone might invest in IVLU to diversify beyond the U.S. and to seek long-term growth from undervalued international stocks. A key risk is that these value stocks, and foreign markets in general, can go up and down significantly with global market conditions.
How much will it cost me?
This ETF has an expense ratio of 0.30%, which means you’ll pay about $3 per year for every $1,000 you invest. That’s a bit higher than the cheapest broad index ETFs, but still reasonable because it tracks a more specialized “value factor” strategy in international markets rather than a plain-vanilla index.
What would affect this ETF?
IVLU could benefit if global growth outside the U.S. improves and investors warm up to value stocks, helping its financial, industrial, and energy holdings like HSBC, Toyota, Shell, and major European banks. On the downside, slower economic conditions in developed markets, falling demand for autos and energy, or tighter banking regulations could hurt its top holdings and weigh on the fund’s performance.
IVLU Top 10 Holdings
IVLU leans heavily on big European banks and healthcare names, giving the fund a distinctly developed-markets ex-U.S. flavor. Financials like HSBC, BNP Paribas, and Banco Santander have been lagging lately, acting as a bit of a brake on performance, while industrial giant Siemens is more steady than spectacular. On the brighter side, pharma leaders Roche and Novartis are rising and helping to pull the fund forward, with Shell adding a relatively steady energy anchor. Overall, it’s a diversified value play abroad, but with clear reliance on European financials and healthcare.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Toyota Motor | 2.14% | $97.89M | JPY 40.36T | 6.88% | 80Outperform | |
| HSBC Holdings | 1.97% | $90.05M | GBP 231.91B | 20.93% | 80Outperform | |
| Shell (UK) | 1.88% | $85.80M | GBP 207.54B | 30.08% | 73Outperform | |
| British American Tobacco | 1.68% | $76.76M | GBP 98.87B | 12.27% | 71Outperform | |
| BNP Paribas | 1.65% | $75.30M | EUR 105.69B | 37.33% | 77Outperform | |
| Roche Holding AG | ― | ― | ― | ― | 73Outperform | |
| Banco Santander | 1.53% | $70.05M | EUR 161.14B | 16.13% | 73Outperform | |
| Siemens | 1.48% | $67.51M | EUR 214.73B | 23.08% | 74Outperform | |
| Sanofi | 1.43% | $65.45M | EUR 105.53B | -3.14% | 75Outperform | |
| Novartis AG | 1.43% | $65.36M | CHF 245.70B | 26.78% | 80Outperform |
IVLU Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IVLU, the sentiment is Positive. The current price of 42.92 is above the 20-day moving average (MA) of 42.49, below the 50-day MA of 43.02, and above the 200-day MA of 41.98, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 52.65 is Neutral, neither overbought nor oversold. The STOCH value of 75.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IVLU.
IVLU Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $42.92 | $45.00(4.85% Upside) | $4.59B | 0.30% | 67Neutral | |
| $44.18 | $47.49(7.48% Upside) | $6.69B | 0.40% | 69Neutral | |
| $46.54 | $53.72(15.43% Upside) | $6.05B | 0.25% | 65Neutral | |
| $57.32 | $71.00(23.86% Upside) | $4.17B | 0.25% | 71Outperform | |
| $50.17 | $63.07(25.71% Upside) | $4.12B | 0.30% | 69Neutral | |
| $41.47 | $48.88(17.88% Upside) | $3.74B | 0.16% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IVLU | iShares MSCI Intl Value Factor ETF | 42.92 | 7.82 | 22.26% | |
| LVHI | Legg Mason International Low Volatility High Dividend ETF | 44.18 | 9.49 | 27.36% | |
| GSIE | Goldman Sachs ActiveBeta International Equity ETF | 46.53 | 6.41 | 15.99% | |
| IDMO | Invesco S&P International Developed Momentum ETF | 57.32 | 5.65 | 10.93% | |
| IMTM | iShares MSCI Intl Momentum Factor ETF | 50.17 | 4.63 | 10.15% | |
| INTF | iShares MSCI Intl Multifactor ETF | 41.47 | 6.16 | 17.45% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
